Recent News

• 06.11.2025 - Veru to Participate in the Virtual BTIG Obesity Health Forum
• 06.11.2025 - Veru to Participate in the Virtual BTIG Obesity Health Forum
• 06.11.2025 - Veru to Participate in the Virtual BTIG Obesity Health Forum
• 05.28.2025 - Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide Alone
• 05.28.2025 - Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide Alone
• 05.28.2025 - Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide Alone
• 05.08.2025 - Veru Participates in a Virtual Investor KOL Connect Segment
• 05.08.2025 - Veru Participates in a Virtual Investor KOL Connect Segment
• 05.08.2025 - Veru Participates in a Virtual Investor KOL Connect Segment
• 05.08.2025 - Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress

Recent Filings

• 06.10.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 06.10.2025 - DEF 14A Other definitive proxy statements
• 05.09.2025 - PRE 14A Other preliminary proxy statements
• 05.08.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.08.2025 - EX-99.1 EX-99.1
• 05.08.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.08.2025 - 8-K Current report
• 05.08.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]